Trials / Completed
CompletedNCT02303444
An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors
RIFTOS MKI - Radioactive Iodine reFractory Asymptomatic Patients in Differentiated Thyroid Cancer - an Observational Study to Assess the Use of Multikinase Inhibitors
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 667 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study was to assess the use of Multikinase Inhibitors (MKIs) in the treatment of patients with a progressive differentiated thyroid carcinoma (DTC) refractory to radioactive iodine (RAI) who do not have any symptoms.
Detailed description
The primary objective of this study was to compare time to symptomatic progression (TTSP) from study entry in asymptomatic patients with RAI-refractory progressive DTC for whom there is a decision to initiate MKIs at study entry with that of asymptomatic patients with RAI-refractory progressive DTC for whom there is a decision to not initiate MKIs at study entry.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib (Nexavar, BAY43-9006) | Patients can get sorafenib at any time during study. |
| DRUG | Other Multikinase inhibitors | Patients can get MKIs at any time during study. |
Timeline
- Start date
- 2015-04-08
- Primary completion
- 2020-06-10
- Completion
- 2020-07-24
- First posted
- 2014-12-01
- Last updated
- 2023-06-08
Locations
34 sites across 19 countries: United States, Algeria, Argentina, Brazil, Egypt, France, Germany, Greece, India, Japan, Lebanon, Mexico, Netherlands, Philippines, Russia, Saudi Arabia, Spain, Taiwan, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT02303444. Inclusion in this directory is not an endorsement.